Quantum-Si Strengthens Commercial, Operations, and Development Teams to Accelerate the Commercial Advancement of the Platinum™ Protein Sequencing Platform
GUILFORD, Conn.–(BUSINESS WIRE)–#theproteinsequencingcompany—Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the appointments of Katherine Atkinson as Senior Vice President of Demand Generation and Corporate Brand, Alex Hutcheson as Senior Vice President of Sales and Service, Christine Nishiyama as Vice President of Supply Chain and Reagent Manufacturing, and John Vieceli, PhD, as Vice President of Algorithms and Data Science.
These appointments follow the commercial launch of Platinum™, the world’s first next-generation, single-molecule protein sequencing platform, and will support Quantum-Si’s growing customer base and further scaling of the company.
Ms. Atkinson is a seasoned executive sales and strategic partnerships leader with more than 20 years of experience in commercial strategy, business development, marketing, corporate branding, and external communications, as well as driving multimillion-dollar revenue growth in both global and startup environments. Most recently, she served as Chief Commercial Officer at Evofem Biosciences. Prior to this, Ms. Atkinson held executive leadership positions at Truvian, Epic Sciences, Edico Genome and Illumina.
Mr. Hutcheson has more than 20 years of experience as a commercial professional within the genomics, biotechnology, and drug discovery markets. Previously, he was Vice President of Sales, North America, at Inscripta. Mr. Hutcheson has a proven track record of commercial success in roles at Pacific Biosciences, where he helped grow the long read sequencing market through multiple new product launches, and at Genetix, Biacore and Beckman Coulter.
Ms. Nishiyama is an experienced supply chain, manufacturing and operations leader, who is passionate about using technology and innovation to help customers succeed. Previously, she served as the Vice President of Operations at Oxford Nanoimaging, where she oversaw manufacturing, supply chain, engineering, customer success, quality assurance, facilities and program management. Prior to this, Ms. Nishiyama also served in various roles at Berkeley Lights, Andor Technology, Hamamatsu Photonics and Raytheon.
Dr. Vieceli brings more than 15 years of experience building and mentoring technical teams, shepherding early-stage technology development to market, and leading strategic programs to his new role. Most recently, he was Senior Principal Bioinformatics Scientist at Illumina where his work on image and signal processing and computer hardware enabled the sub-$1,000 genome. Dr. Vieceli has also held leadership positions at Omniome and Pacific Biosciences. He received his Ph.D. in Theoretical Physical Chemistry from UC Santa Cruz.
“The additions of Katherine, Alex, Christine and John to our team reflect how attractive and promising our approach to protein sequencing is seen by the broader industry,” said Jeff Hawkins, Quantum-Si’s Chief Executive Officer. “We have the people, product and commercial scalability to put Platinum in the hands of researchers and clinicians everywhere.”
Platinum is the world’s first next-generation single-molecule protein sequencing platform whose methodology involves kinetic (binding) signatures that recognize proteins and amino acids and their chemical changes based on kinetic properties. Its elegant simplicity enables broad-scale access to proteomic data, making it a critical instrument for the future of proteomics research. With its small benchtop design and low price-point, Platinum is poised to accelerate breakthroughs across scientific disciplines, from drug discovery to biotech, and help people live healthier and longer lives.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; our ongoing leadership transition; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and servicesthat serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report for the fiscal year ended December 31, 2022, and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.